The effect of elexacaftor/tezacaftor/ivacaftor on non-pulmonary symptoms in adults with cystic fibrosis

Background: Elexacaftor/Tezacaftor/Ivacaftor (ETI) is a CFTR modulator that has led to large benefits in lung function, pulmonary exacerbation rates, and respiratory symptoms. Less is known about the effect of ETI on non-pulmonary symptoms. The objective of this study was to examine the changes in p...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Sarah Allgood, Reena Levy, Despina Bubaris, Kristin Riekert, Kevin J. Psoter, Noah Lechtzin
বিন্যাস: প্রবন্ধ
ভাষা:English
প্রকাশিত: Elsevier 2023-09-01
মালা:Heliyon
অনলাইন ব্যবহার করুন:http://www.sciencedirect.com/science/article/pii/S2405844023073188